Abstract | OBJECTIVE: METHODS: A systematic review was performed. A systematic search was conducted in PubMed/MEDLINE, Scopus, Web of Science and the Cochrane library databases on RTX, and an extensive literature search was conducted on other biologic agents. RESULTS: Forty-five papers pertinent to our questions were found: 16 retrospective cohort studies, 8 case series, 3 prospective cohort studies and 18 single case reports, for a total of 368 EGPA patients. More than 80% of evaluable patients achieved complete or partial remission with a tendency towards a higher rate of complete response in the pANCA-positive subgroup. CONCLUSION: Although the majority of the evaluable EGPA patients treated with RTX appears to achieve complete remission, we strongly believe that a number of sources of heterogeneity impair a clear interpretation of results and limit their transferability in clinical practice. Differences in design, enrolment criteria, outcome definition and measurement make a comparison among data obtained from studies on RTX and other biologic agents unreliable.
|
Authors | Vincenzo G Menditto, Giulia Rossetti, Diletta Olivari, Alessia Angeletti, Marco Rocchi, Armando Gabrielli, Giovanni Pomponio |
Journal | Rheumatology (Oxford, England)
(Rheumatology (Oxford))
Vol. 60
Issue 4
Pg. 1640-1650
(04 06 2021)
ISSN: 1462-0332 [Electronic] England |
PMID | 33471122
(Publication Type: Journal Article, Systematic Review)
|
Copyright | © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Immunosuppressive Agents
- Rituximab
|
Topics |
- Granulomatosis with Polyangiitis
(drug therapy)
- Humans
- Immunosuppressive Agents
(therapeutic use)
- Observational Studies as Topic
- Remission Induction
- Rituximab
(therapeutic use)
- Treatment Outcome
|